No Stock Yet
Kunming Pharmaceutical Group (600422): Short-term pressure on performance affected by harvesting and the epidemic is optimistic about future business development
Incident: On March 22, Kunming Pharmaceutical Group released its 2022 annual report. In 2022, the company achieved total revenue of 8.282 billion yuan, an increase of 0.35% over the previous year; achieved net profit of 383 million yuan, a decrease of 24.52% over the previous year; and realized operating profit of 497 million yuan, a decrease of 21.59% over the previous year. Comment: Revenue is at the same level due to collection and the impact of the epidemic, and there are prospects for growth due to the lifting of the medical insurance suffix for injectable formulations. 22Q4 The company achieved operating income of 2,089 million yuan (-6.15%) and net profit of 11 million yuan to the mother (-85.
Kunming Pharmaceutical Group (600422.SH): Net profit fell 24.52% to 383 million yuan in 2022, plans to distribute 1.60 yuan in 10
Gelonghui, March 22, 丨 Kunming Pharmaceutical Group (600422.SH) announced its 2022 annual report. It achieved operating income of 8.282 billion yuan, an increase of 0.35% over the previous year; net profit attributable to shareholders of listed companies was 383 million yuan, a decrease of 24.52% over the previous year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 251 million yuan, a decrease of 10.17% over the previous year; and basic earnings per share of 0.51 yuan. It is proposed to distribute a cash dividend of 1.60 yuan (tax included) for every 10 shares to all shareholders.
Kunming Pharmaceutical Group (600422.SH): The amount of financing to be applied to financial institutions in 2023 will not exceed 2,616 billion yuan
Gelonhui, March 22, 丨 Kunming Pharmaceutical Group (600422.SH) announced that in order to meet operating and development needs and expand corresponding financing channels, the company and its subsidiaries plan to apply for a financing amount not exceeding RMB 2,616 million from financial institutions in 2023. The final amount is subject to the amount actually approved by each financial institution.
Is KPC Pharmaceuticals (SHSE:600422) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.' So it might
Kunming Pharmaceutical Group (600422): Short-term factors put pressure on the company's performance, which can be expected in the future
According to the zinc strategy opinion, zinc prices fluctuated narrowly yesterday. I am concerned that changes in macro-sentiment are interfering with prices. On the supply side, the refinery currently has relatively sufficient inventory. The average raw material reserve is about 1 month, and the smelter is still quite active in starting production. On the demand side, sales of galvanized pipes are relatively good. At the same time, enterprises in northern Hebei, Shandong and other places with production restrictions due to environmental protection have basically returned to normal, which has led to an increase in the operating rate of galvanized steel, while domestic orders for galvanized structural parts have not performed well yet. Overall, the upper zinc price is constrained by factors such as macro pressure and expectations of increased overseas supply, and the bottom is supported by low inventories. In the short term, fluctuations in the zinc price range are the main ones. It is recommended to sell high
Chinese medicine stocks fell collectively, and Kunming Pharmaceutical Group fell nearly 9%
Gelonhui, March 20, 丨 Kunming Pharmaceutical Group fell nearly 9%, China Resources 39, Xintian Pharmaceutical, and Fangsheng Pharmaceutical fell more than 5%, and Jichuan Pharmaceutical, Baiyunshan, and Jiuzhitang declined one after another.
Galaxy Securities: Pharmaceutical product collection continues to advance, and the impact of generic drug collection on the industry may be nearing its end
KPC Pharmaceuticals, Inc. (SHSE:600422) Stock Most Popular Amongst Retail Investors Who Own 47%, While Private Companies Hold 39%
Key Insights KPC Pharmaceuticals' significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 8 investors have a majority
Kunming Pharmaceutical Group (600422): Single Gold Products Drive Category Cluster Channel Optimization Drives Performance Improvement
Company Profile As a leader in the 37 industry, the company relies on the advantages of Kunyaku Seitong and Kunming Traditional Chinese Medicine brands to drive the development of category clusters and drive continuous improvement in performance. In 2017-2021, the average compound annual growth rate of the company's revenue and net profit returned to the mother was 9% and 11%. The first three quarters of 2022 achieved revenue of 6.2 billion yuan (+3%); net profit of the mother was 3.7 billion yuan (-14%). On January 19, 2023, the company completed the restructuring of the board of directors and was officially merged into China Resources 39. Investment logic: China Resources 39 Holdings holds 28%, and the product structure continues to be optimized. May 9, 2022
Kunming Pharmaceutical Group was forced to execute 340,000
No Stock Yet